Bide Pharmatech Future Growth
Future criteria checks 4/6
Bide Pharmatech is forecast to grow earnings and revenue by 28.1% and 14.6% per annum respectively. EPS is expected to grow by 27.8% per annum. Return on equity is forecast to be 7.3% in 3 years.
Key information
28.1%
Earnings growth rate
27.8%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 14.6% |
| Future return on equity | 7.3% |
| Analyst coverage | Low |
| Last updated | 19 Sep 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,533 | 176 | N/A | -1 | 2 |
| 12/31/2025 | 1,338 | 147 | N/A | -2 | 2 |
| 12/31/2024 | 1,173 | 123 | N/A | 74 | 2 |
| 9/30/2024 | 1,098 | 80 | 56 | 166 | N/A |
| 6/30/2024 | 1,101 | 78 | 22 | 78 | N/A |
| 3/31/2024 | 1,102 | 99 | -44 | 12 | N/A |
| 12/31/2023 | 1,092 | 110 | -118 | -57 | N/A |
| 9/30/2023 | 1,050 | 161 | -141 | -89 | N/A |
| 6/30/2023 | 988 | 171 | -65 | -23 | N/A |
| 3/31/2023 | 909 | 157 | 35 | 73 | N/A |
| 12/31/2022 | 834 | 146 | -9 | 30 | N/A |
| 9/30/2022 | 768 | 129 | -38 | -21 | N/A |
| 6/30/2022 | 707 | 114 | -45 | -28 | N/A |
| 3/31/2022 | 649 | 101 | -141 | -115 | N/A |
| 12/31/2021 | 606 | 98 | -94 | -65 | N/A |
| 12/31/2020 | 391 | 59 | -34 | 4 | N/A |
| 12/31/2019 | 249 | -1 | -2 | 3 | N/A |
| 12/31/2018 | 163 | -19 | -16 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688073's forecast earnings growth (28.1% per year) is above the savings rate (2.8%).
Earnings vs Market: 688073's earnings (28.1% per year) are forecast to grow faster than the CN market (26.2% per year).
High Growth Earnings: 688073's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688073's revenue (14.6% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 688073's revenue (14.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688073's Return on Equity is forecast to be low in 3 years time (7.3%).